Scientific Publications in Peer-Reviewed Journals
Virtually full recovery for inactivated hepatitis C virus using membrane-based SXC:
Lothert K, et al. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.
Scientific Reports 2020;1016261.
Membrane-based SXC is used as a capture step for the purification of Orf virus with 84% product yield:
Lothert K, et al. Selection of chromatographic methods for the purification of cell culture-derived Orf virus for its application as a vaccine or viral vector.
J Biotech 2020;323:62–72.
Our purification technology can achieve >98% yield for 7 different AAV serotypes and recombinant variants using a single standardized setup:
Marichal-Gallardo P, et al. Single-use purification of adeno-associated viral gene transfer vectors by membrane-based steric exclusion chromatography. 2020, in revision.
Our tubular bioreactor could continually produce influenza A virus for over 3 weeks and is the only production system that avoids the accumulation of defective interfering particles:
Our purification technology achieves 20–40% more yield (>98%) for influenza A virus compared to existing purification methods by using a disposable device:
J Chromatogr A 2017;1483:110–119.
We show stable continuous production of MVA virus for over 3 weeks using a cascade of two stirred tanks:
Review article with the latest trends in continuous cultivations of suspension cells for the production of virus particles:
Appl Microbiol Biotechnol 2016;100:2121–2132.
Conference Talks & Posters
Conference Talks
Our purification technology is the only single-use chromatography method which purifies a wide variety of viruses (influenza virus, yellow fever virus, Vaccinia virus, AAV) with typical yields above 95% at high flow rate using a one-size-fits-all setup:
Marichal-Gallardo P, et al.
A single-use chromatographic purification platform for viral gene transfer vectors & viral vaccines.
Advancing Manufacture of Cell and Gene Therapies VI
Coronado, CA, USA. January 2019
Our purification technology yielded more than 100 000 doses of yellow fever vaccine in less than 3 hours without product losses and with impurity levels below the regulatory requirements for human vaccines:
Marichal-Gallardo P, et al.
Purifying viruses with a sheet of paper: Single-use steric exclusion chromatography as a capture platform for vaccine candidates.
Vaccine Technology VII
Mont Tremblant, Canada. June 2018
Our production technology has 20x smaller volumes is the only bioreactor system that enables stable virus production over weeks and without accumulation of mutant viruses.
Tapia, F, et al.
Multi-stage bioreactor concepts for continuous virus vaccine production.
Continuous Biomanufacturing: Achievements and Challenges for Commercial Implementation
Oxford, UK, 2018
Patents
WO2017190790A1, Tapia F, et al. Plug flow tubular bioreactor, system containing the same and method for production of virus. (Pending)
WO2017076553A1, Wolff MW, et al. Method for the separation of virus compositions including depletion and purification thereof. (Pending)